

DIVI'S LABORATORIES LIMITED

**UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER
AND HALF-YEAR ENDED 30TH SEPTEMBER, 2005**

(Rs.in Lakhs)

	Particulars	Unaudited				Audited
		Quarter ended 30.09.2005	Quarter ended 30.09.2004	Half-Year ended 30.09.2005	Half-Year ended 30.09.2004	Year Ended 31.03.2005
		(1)	(2)			(5)
1	Net Sales/Income from operations (net of Excise Duty)	8139.14	7546.70	14603.56	13682.04	34737.83
2	Other Income	219.00	307.37	588.55	783.22	1714.65
3	Total Income:	8358.14	7854.07	15192.11	14465.26	36452.48
4	Expenditure:					
	a. (Increase) / Decrease in Stock	(715.41)	(1645.73)	(2743.43)	(2606.53)	(2524.03)
	b. Consumption of Raw Material	4093.93	4732.01	8399.21	7671.29	18362.29
	c. Staff Cost	395.48	372.69	788.66	735.76	1509.63
	d. Other Expenditure:					
	- Manufacturing Expenses	850.89	835.04	1627.40	1589.94	3284.14
	- Other expenses	868.51	873.66	1852.60	1711.30	3652.46
5	Finance charges	93.90	83.65	207.76	149.05	429.89
6	Depreciation	365.20	382.96	726.33	746.44	1506.68
7	Total Expenses:	5952.50	5634.28	10858.53	9997.25	26221.06
8	Profit Before Tax (3-7)	2405.64	2219.79	4333.58	4468.01	10231.42
	Provision for Taxation					
9	- Current Tax	769.00	756.00	1410.00	1475.00	3353.82
	- Deferred Tax	41.62	115.77	50.14	211.09	274.48
	- Fringe Benefit Tax	2.93	--	5.54	--	--
10	Net Profit: (8-9)	1592.09	1348.02	2867.90	2781.92	6603.12
11	Paid-up Equity Share Capital	1281.87	1281.87	1281.87	1281.87	1281.87
12	Reserves excluding revaluation reserves					27084.12
13	Earnings Per Share Rs. - Basic/Diluted (Face Value : Rs.10 per share)	12.42	10.52	22.37	21.70	51.51
14	Aggregate of non-promoting shareholding					
	- No. of shares	5898259	5894700	5898259	5894700	5897759
	- Percentage of shareholding	46.01%	45.99%	46.01%	45.99%	46.01%

NOTES:

1. The above results for the quarter and half-year ended 30th September, 2005, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 28th October, 2005.
2. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 on Segment Reporting issued by the Institute of Chartered Accountants of India.
3. The figures for the previous period have been regrouped, wherever necessary.
4. Information on Investor complaints pursuant to Clause 41 of the Listing Agreement for the quarter ended 30th September, 2005:

Nature of Complaints	Pending as at 01-07-2005	Received during the quarter	Disposal during the quarter	Lying unresolved as at 30-09-2005
Share Certificates related	0	0	0	0
Dividend related	0	2	2	0

for Divi's Laboratories Limited

Hyderabad
28.10.2005

Dr. Murali K. Divi
Chairman & Managing Director